1.0Najafi Capital Deal Making Platformhttps://najafi.capital/pladminhttps://najafi.capital/pl/author/admin/rich600338<blockquote class="wp-embedded-content" data-secret="HS6tTkhYtI"><a href="https://najafi.capital/pl/individual-investor/individual-angel-john-ballantyne/">#ERROR!</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://najafi.capital/pl/individual-investor/individual-angel-john-ballantyne/embed/#?secret=HS6tTkhYtI" width="600" height="338" title="„Individual/Angel: John Ballantyne” — Najafi Capital Deal Making Platform" data-secret="HS6tTkhYtI" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://najafi.capital/wp-includes/js/wp-embed.min.js </script>John Ballantyne is a founder of Agathos Biologics. He co-founded Aldevron with Michael Chambers in 1998 and has been the Chief Scientific Officer since its establishment. His innovative work at Aldevron includes creation of the GMP Source product line and collaborative research with military scientists in the development of vaccine and passive-based countermeasures to lethal […]